Policies for biosimilar uptake in Europe: An overview

PLoS ONE

Volumn 12, Issue 12, 2017, Pages

  Moorkens, Evelien ^a   Vulto, Arnold G ^b   Huys, Isabelle ^a   Dylst, Pieter ^a,c   Godman, Brian ^d,e   Keuerleber, Simon ^f   Claus, Barbara ^g   Dimitrova, Maria ^h   Petrova, Guenka ^h   Sović Brkičić, Ljiljana ⁱ   Slabý, Juraj ^j   Šebesta, Robin ^j   Laius, Ott ^k,l   Karr, Allan ^m   Beck, Morgane ⁿ   Martikainen, Jaana E ^o   Selke, Gisbert W ^p   Spillane, Susan ^q,r   McCullagh, Laura ^q,r   Trifirò, Gianluca ^s   Bonanno, Patricia Vella ^e   Mack, Asbjørn ^t   Fogele, Antra ^u   Viksna, Anita ^u   Władysiuk, Magdalena ^v   Mota Filipe, Helder ^w   Meshkov, Dmitry ^x   Kalaba, Marija ^y   Bedrač, Simona Mencej ^z   Fürst, Jurij ^aa   Zara, Corrine ^ab   Skiöld, Peter ^ac   Magnússon, Einar ^ad   Simoens, Steven ^a   more..

^a UNIVERSITY OF LEUVEN   (Belgium)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c Medicines for Europe   (Belgium)

^d KAROLINSKA INSTITUTE   (Sweden)

^e UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^f Main Assoc of Austrian Social Security Institutions   (Austria)

^g GHENT UNIVERSITY   (Belgium)

^h MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

ⁱ Croatian Health Insurance Agency   (Croatia)

^j State Institute for Drug Control   (Czech Republic)

^k State Agency of Medicines   (Estonia)

^l UNIVERSITY OF TARTU   (Estonia)

^m Karr Consultancy Ltd   (United Kingdom)

ⁿ OMEDIT Agence régionale de santé Grand Est   (France)

^o SOCIAL INSURANCE INSTITUTION   (Finland)

^p Wissenschaftliches Institut der AOK WIdO   (Germany)

^q TRINITY COLLEGE DUBLIN   (Ireland)

^r ST JAMES S HOSPITAL   (Ireland)

^s UNIVERSITY OF MESSINA   (Italy)

^t Norwegian Hospital Procurement Trust   (Norway)

^u National Health Service   (Latvia)

^v HTA CONSULTING   (Poland)

^w RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

^x N A SEMASHKO NATIONAL RESEARCH INSTITUTE OF PUBLIC HEALTH   (Russian Federation)

^y Primary healthcare center Zemun ^*  (Serbia)

^z Agency for Medicinal Products and Medical Devices of the Republic of Slovenia   (Slovenia)

^aa Health Insurance Institute   (Slovenia)

^ab C Agy Hlth Technol Assess Res   (Spain)

^ac Dental and Pharmaceutical Benefits Agency   (Sweden)

^ad Ministry of Welfare   (Iceland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOSIMILAR AGENT; ETANERCEPT; FILGRASTIM; HUMAN GROWTH HORMONE; INFLIXIMAB; INSULIN GLARGINE; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT FOLLITROPIN;

DRUG COST; DRUG INFORMATION; DRUG MARKETING; DRUG UTILIZATION; EUROPE; GEOGRAPHIC DISTRIBUTION; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEALTH EDUCATION; HUMAN; PHARMACIST; REIMBURSEMENT; REVIEW; ECONOMICS;

BIOSIMILAR PHARMACEUTICALS; DRUG COSTS; EUROPE; HUMANS;

EID: 85039798764     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0190147     Document Type: Review

References (48)

1. Geynisman DM, De Velasco G, Sewell KL, Jacobs I. Biosimilar biologic drugs: a new frontier in medical care. Postgrad Med. 2017; 129(4):460–70. https://doi.org/10.1080/00325481.2017.1311196 PMID: 28343424
2. Outlook for global medicines through 2021—Balancing cost and value. Parsippany: QuintilesIMS Institute; 2016.
3. Kawalec P, Stawowczyk E, Tesar T, Skoupa J, Turcu-Stiolica A, Dimitrova M, et al. Pricing and Reimbursement of Biosimilars in Central and Eastern European Countries. Front Pharmacol. 2017; 8:288. https://doi.org/10.3389/fphar.2017.00288 PMID: 28642700
4. Delivering on the potential of biosimilar medicines—The role of functioning competitive markets. IMS institute for healthcare informatics; 2016.
5. Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use. Official Journal of the European Union. 2001 (L 311):67–128
6. EC. Regulation (EC) 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency. Official Journal of the European Union. 2004; 1:L 136/1—L /33
7. EMA. Guideline on similar biological medicinal products 2014 [22/01/2016] Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf.
8. European Medicines Agency—Multidisciplinary—Multidisciplinary: biosimilar: EMA; 2017 [05/06/2017] Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000408.jsp&mid=WC0b01ac058002958c.
9. European Medicines Agency—Find medicine—European public assessment reports: EMA; 2017 [26/ 04/2017] Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d124&searchTab=searchByAuthType&keyword=Enter% 20keywords&searchType=name&alreadyLoaded=true&status=Authorised&jsenabled=false&search GenericType=biosimilars&orderBy=authDate&pageNo=1.
10. The impact of biosimilar competition. London: IMS Health; 2016.
11. Ingrasciotta Y, Giorgianni F, Bolcato J, Chinellato A, Pirolo R, Tari DU, et al. How Much Are Biosimilars Used in Clinical Practice? A Retrospective Italian Population-Based Study of Erythropoiesis-Stimulating Agents in the Years 2009–2013. BioDrugs. 2015; 29(4):275–84. https://doi.org/10.1007/s40259-015-0132-7 PMID: 26169209
12. EBE. What pricing and reimbursement policies to use for off-patent biologicals?—Results from the EBE 2014 biological medicines policy survey. Generics and Biosimilars Initiative Journal (GaBi Journal). 2015; 4(1):17–24
13. Rémuzat C, Dorey J, Cristeau O, Ionescu D, Radiere G, Toumi M. Key drivers for market penetration of biosimilars in Europe. J Mark Access Health Policy. 2017; 5(1):1272308. https://doi.org/10.1080/20016689.2016.1272308 PMID: 28265349
14. Rémuzat C, Kapuśniak A, Caban A, Ionescu D, Radière G, Mendoza C, et al. Supply-side and demand-side policies for biosimilars: an overview in 10 European member states. Journal of Market Access & Health Policy. 2017; 5(1).DOI: https://doi.org/10.1080/20016689.2017.1307315 PMID: 28740617
15. Renwick MJ, Smolina K, Gladstone EJ, Weymann D, Morgan SG. Postmarket policy considerations for biosimilar oncology drugs. Lancet Oncol. 2016; 17(1):e31–8. https://doi.org/10.1016/S1470-2045(15) 00381-2 PMID: 26758759
16. Dylst P, Vulto AG, Simoens S. Analysis of Spanish generic medicines retail market: recommendations to enhance long-term sustainability. Expert Rev Pharmacoecon Outcomes Res. 2014; 14(3):345–53. https://doi.org/10.1586/14737167.2014.891442 PMID: 24758569
17. Lepage-Nefkens I, Gerkens S, Vinck I, Piérart J, Hulstaert F, Farfan-Portet M. Barriers and opportunities for the uptake of biosimilar medicines in Belgium. Health Services Research (HSR) Brussels: Belgian Health Care Knowledge Centre (KCE); 2013. Report No.: KCE Report 199. D/2013/10.273/13 Contract No.: KCE Report 199. D/2013/10.273/13.
18. Wettermark B, Godman B, Jacobsson B, Haaijer-Ruskamp FM. Soft regulations in pharmaceutical policy making: an overview of current approaches and their consequences. Appl Health Econ Health Policy. 2009; 7(3):137–47. https://doi.org/0.2165/11314810-000000000-00000 PMID: 19799468
19. Piperska Group—Rational Prescribing | Piperska Group:: Piperska Group; [22/11/2017] Available from: http://www.piperska.org/.
20. Adamski J, Godman B, Ofierska-Sujkowska G, Osinska B, Herholz H, Wendykowska K, et al. Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. BMC Health Serv Res. 2010; 10:153. https://doi.org/10.1186/1472-6963-10-153 PMID: 20529296
21. Godman B, Finlayson AE, Cheema PK, Zebedin-Brandl E, Gutierrez-Ibarluzea I, Jones J, et al. Personalizing health care: feasibility and future implications. BMC Med. 2013; 11:179. https://doi.org/10.1186/ 1741-7015-11-179 PMID: 23941275
22. Godman B, Malmstrom RE, Diogene E, Gray A, Jayathissa S, Timoney A, et al. Are new models needed to optimize the utilization of new medicines to sustain healthcare systems? Expert Rev Clin Pharmacol. 2015; 8(1):77–94. https://doi.org/10.1586/17512433.2015.990380 PMID: 25487078
23. Godman B, Petzold M, Bennett K, Bennie M, Bucsics A, Finlayson AE, et al. Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources? Findings from across Europe and their implications. BMC Med. 2014; 12:98. https://doi.org/10.1186/1741-7015-12-98 PMID: 24927744
24. Godman B, Shrank W, Andersen M, Berg C, Bishop I, Burkhardt T, et al. Policies to enhance prescribing efficiency in europe: findings and future implications. Front Pharmacol. 2010; 1:141. https://doi.org/10.3389/fphar.2010.00141 PMID: 21833180
25. Moon JC, Godman B, Petzold M, Alvarez-Madrazo S, Bennett K, Bishop I, et al. Different initiatives across Europe to enhance losartan utilization post generics: impact and implications. Front Pharmacol. 2014; 5:219. https://doi.org/10.3389/fphar.2014.00219 PMID: 25339902
26. Ermisch M, Bucsics A, Vella Bonanno P, Arickx F, Bybau A, Bochenek T, et al. Payers’ Views of the Changes Arising through the Possible Adoption of Adaptive Pathways. Front Pharmacol. 2016; 7:305. https://doi.org/10.3389/fphar.2016.00305 PMID: 27733828
27. Dorner T, Strand V, Cornes P, Goncalves J, Gulacsi L, Kay J, et al. The changing landscape of biosimilars in rheumatology. Ann Rheum Dis. 2016; 75(6):974–82. https://doi.org/10.1136/annrheumdis-2016-209166 PMID: 26964144
28. WHO | International Classification of Diseases: World Health Organization; 2016 [20/11/2017] Available from: http://www.who.int/classifications/icd/en/.
29. Convention 2016—Nouvelle ROSP: l’Assurance Maladie; 2017 [20/11/2017] Available from: http://convention2016.ameli.fr/valoriser-lactivite/nouvelle-rosp/.
30. Toekomstpact voor de patiënt met de farmaceutische industrie (Pact of the future for the patient with the pharmaceutical industry) 2015 [08/06/2017] Available from: http://www.deblock.belgium.be/sites/default/files/articles/20150727%20toekomstpact.pdf.
31. Convenant Doorstart voor biosimilaire geneesmiddelen in België (Covenant on the re-launch of biosimilar medicines in Belgium) 2016 [08/06/2017] Available from: http://www.inami.fgov.be/SiteCollectionDocuments/convenant_biosimilaire_geneesmiddelen_belgie.pdf.
32. ‘Goedkoop voorschrijven’: nieuwe definitie vanaf 1 januari 2015: RIZIV; 2017 [08/06/2017] Available from: http://www.riziv.fgov.be/nl/professionals/individuelezorgverleners/artsen/verzorging/Paginas/goedkoop-voorschrijven-20150101.aspx#.WTh9WdwlHIU.
33. Biosimilars in the EU—Information guide for healthcare professionals: European Medicines Agency, European Commission; 2017 [08/06/2017] Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Leaflet/2017/05/WC500226648.pdf.
34. Rahmenvertrag über die Arzneimittelversorgung nach §129 Absatz 2 SGB V 2016 [08/06/2017] Available from: https://www.abda.de/fileadmin/assets/Vertraege/Rahmenvertrag_ueber_die_Arzneimittelversorgung_nach_Paragraf_129_Absatz_2_SGB_V_20160930.pdf.
35. Moorkens E, Meuwissen N, Huys I, Declerck P, Vulto A, Simoens S. The Market of Biopharmaceutical Medicines: A Snapshot of a Diverse Industrial Landscape. Front Pharmacol. 2017.doi: https://doi.org/10.3389/fphar.2017.00314 PMID: 28642701
36. Reiland J, Freischem B, Roediger A. What pricing and reimbursement policies to use for off-patent biologicals in Europe?—results from the second EBE biological medicines policy survey. Generics and Biosimilars Initiative Journal (GaBi Journal). 2017; 6(2):61–78.DOI: https://doi.org/10.5639/gabij.2017.0602.014
37. Jacobs I, Singh E, Sewell KL, Al-Sabbagh A, Shane LG. Patient attitudes and understanding about biosimilars: an international cross-sectional survey. Patient Prefer Adherence. 2016; 10:937–48. https://doi.org/10.2147/PPA.S104891 PMID: 27307714
38. Pasina L. C G, Nobili. A survey among hospital specialists and pharmacists about biosimilars. European Journal of Internal Medicine. 2016; 35:e31–3. http://dx.doi.org/10.1016/j.ejim.2016.07.010 PMID: 27461988
39. Beck M, Michel B, Rybarczyk-Vigouret MC, Leveque D, Sordet C, Sibilia J, et al. Knowledge, behaviors and practices of community and hospital pharmacists towards biosimilar medicines: Results of a French web-based survey. MAbs. 2017; 9(2):383–90. https://doi.org/10.1080/19420862.2016.1267087 PMID: 27929743
40. What I need to know about biosimilar medicines—Information for patients: European Commission; 2016 [30/06/2017] Available from: http://ec.europa.eu/DocsRoom/documents/20961.
41. What you need to know about biosimilar medicinal products—A consensus information document: European Commission; 2013 [24/09/2015] Available from: http://ec.europa.eu/DocsRoom/documents/8242.
42. Baumgärtel C. Austria increases dialogue in order to involve physicians more with biosimilars. Generics and Biosimilars Initiative Journal (GaBi Journal). 2013; 2(1). https://doi.org/10.5639/gabij.2013.0201. 003
43. Li E, Liu J, Ramchandani M. A Framework for Integrating Biosimilars Into the Didactic Core Requirements of a Doctor of Pharmacy Curriculum. Am J Pharm Educ. 2017; 81(3):57. https://doi.org/10.5688/ ajpe81357 PMID: 28496277
44. Schiestl M, Krendyukov A. The ESMO position paper on biosimilars in oncology: enhancing the provision of accurate education and information. ESMO Open. 2017; 2(3):e000245. https://doi.org/10.1136/ esmoopen-2017-000245 PMID: 29071126
45. Broccoli A, Argnani L, Stefoni V, Gandolfi L, Zinzani PL. Efficacy and safety of biosimilar epoetin alpha in patients with chronic lymphoid neoplasms and chemotherapy-induced anaemia: An observational, retrospective, monocentric analysis. Hematol Oncol. 2017. https://doi.org/10.1002/hon.2412 PMID: 28332724
46. Markenson J, Alvarez DF, Jacobs I, Kirchhoff C. A practical guide about biosimilar data for health care providers treating inflammatory diseases. Biologics. 2017; 11:13–21. https://doi.org/10.2147/BTT. S122335 PMID: 28280299
47. Zheng MK, Shih DQ, Chen GC. Insights on the use of biosimilars in the treatment of inflammatory bowel disease. World J Gastroenterol. 2017; 23(11):1932–43. https://doi.org/10.3748/wjg.v23.i11.1932PMID: 28373759
48. Jorgensen KK, Olsen IC, Goll GL, Lorentzen M, Bolstad N, Haavardsholm EA, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017. https://doi.org/10.1016/S0140-6736(17)30068-5